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Themetastatic spread of tumor cells is the major risk factor affecting the clinical prognosis of colorectal cancer (CRC) patients.The
metastatic phenotype can bemodulated by dysregulating the synthesis of different structural and functional proteins of tumor cells.
Micro(mi)RNAs are noncoding RNAs that recognize their cognate messenger (m)RNA targets by sequence-specific interactions
with the 3󸀠 untranslated region and are involved in the multistep process of CRC development. The objective of this study was to
investigate the expression and biological roles of miR-224 in CRC. The miR-224 expression level was assessed by a quantitative
real-time PCR in 79 CRC and 18 nontumor tissues. Expression levels of miR-224 in CRC tissues were significantly lower than those
in nontumor tissues. Its expression level was associated with the mutation status of the APC gene. Ectopic expression of miR-224
suppressed the migratory ability of CRC cell line, but cell proliferation was less affected. Increased miR-224 diminished Cdc42
and SMAD4 expressions at both the protein and mRNA levels and inhibited the formation of actin filaments. Overall, this study
indicated a role of miR-224 in negatively regulating CRC cell migration.The expression level of miR-224 may be a useful predictive
biomarker for CRC progression.
1. Introduction
Colorectal cancer (CRC) is currently one of the leading causes
of cancer mortality and the third most common malignant
neoplasmworldwide.Themajor cause of colon cancer-related
mortality is due to livermetastasis, and approximately 60% of
colon cancer patients are expected to develop metastases [1].
The 5-year survival rate of CRC patients is 91% if the disease
is diagnosed while still localized, but only 70% for regional
disease, and this declines to 11% once distant metastasis has
occurred [2]. In terms of the clinical relevance of a CRC
prognosis and the status of metastasis, understanding the
underlying mechanisms of CRC tumorigenesis and metas-
tasis will contribute to validating therapeutic targets and
improving clinical applications for treating CRC patients.
Micro(mi)RNAs are small RNA molecules (18∼25
nucleotides in length) that function as posttranscriptional
regulators of gene expression in various species. More
than 50% of miRNA genes are located in cancer-associated
genomic regions or in fragile sites, indicating that miRNA
expression signatures may partly reflect genetic alterations
in the progression of human cancers [3]. miRNAs recognize
their target(s) by sequence-specific interactions with the
3󸀠 untranslated regions (UTRs) of cognate mRNA targets
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and repress their translation or modify their stability, which
regulates the physiological or disease-associated biological
process [4–6]. Several studies reported that miRNAs
participate in CRC by modulating certain gene expressions
in response to tumorigenesis and metastasis. The tumor-
suppressor, Pdcd4, is negatively regulated by miR-21, thereby
stimulating invasion, intravasation, and metastasis in CRC
[7]. miR-135a and miR-135b are upregulated in CRC, and this
was correlated with a reduction in adenomatous polyposis
coli (APC) gene expression [8]. In turn, miR-143 andmiR-145
were expressed at reduced levels in colon cancer epithelial
cells [9], and in vitro transfection with either an miR-143 or
miR-145 precursor construct led to cell growth inhibition
by targeting ERK 5 and insulin receptor substrate-1 [10, 11].
A recent global miRNA expression analysis indicated that
miR-143 and miR-145 also appear to function in opposing
manners to either inhibit or augment cell proliferation in
a metastatic CRC cell model [12]. miR-126, which is also
frequently lost in colon cancers, can suppress the growth of
neoplastic cells by targeting phosphatidylinositol 3-kinase
signaling [13]. Transiently transfected miR-196a can promote
significant decreases in adhesion and increases in migration
and invasion, but not in proliferation or apoptosis of SW480
colon cancer cells [14].
The dysregulated expression of miR-224 was reported
in several human cancers. It was suggested that miR-224
was involved in cell proliferation, migration, invasion, and
apoptosis; however, its potential functions as an oncogene or
tumor suppressor remain contradictory. The expression level
of miRNA-224 is upregulated in hepatocellular carcinoma
[15], pancreatic ductal adenocarcinomas [16], breast cancer
[17], perineural invasion prostate cancer [18], and clear cell
renal cell carcinoma [19], while it is downregulated in breast
[20], lung [21], prostate [22], oral [23], and ovarian cancers
[24]. In CRC, gain of miR-224 was reported from a global
miRNA array analysis [12], and the expression was related
to the status of DNA mismatch repair [25], drug resistance
[26], and the progression of inflammatory bowel disease [27].
Accordingly, we postulated that miR-224 may play a crucial
role in regulating the clinical characteristics of CRC, and its
expression level might be a useful predictive biomarker of
CRC progression.
2. Materials and Methods
2.1. Study Subjects. Frozen tissue samples were retrospec-
tively obtained from 79 patients who underwent surgical
resection for CRC at the Department of Surgery, Chung Shan
Medical University Hospital, between December 2003 and
December 2007. Before the resected specimens were collected
and used, informed written consent was obtained from all
subjects and/or their guardians. The acquisition of samples
and their subsequent examination were approved by the
institutional review board of Chung ShanMedical University.
None of the participants had a previous history of cancer.The
clinical stages and pathological features of primary tumors
were defined according to the criteria of the American Joint
Commission on Cancer. Among these 79 patients, 18 patients
with tumor and matched adjacent tissue specimens were
firstly applied for the examination of miR-224 expression.
Thereafter, 61 patients’ specimens with known TP53 and APC
status were added and undergone further analysis.
2.2. DNA Sequencing. Mutations in the APC and TP53 genes
were determined by direct sequencing of polymerase chain
reaction (PCR) products amplified from the DNA of tumor
samples as previously described [28, 29]. Four sets of oligonu-
cleotide primers (A1: 5󸀠-CAGACTTATTGTGTAGAAGA-3󸀠
and A2: 5󸀠-CTCCTGAAGAAAATTCAACA-3󸀠 for codons
1260 to 1359; B1: 5󸀠-AGGGTTCTAGTTTATCTTCA-3󸀠 and
B2: 5󸀠-TCTGCTTGGTGGCATGGTTT-3󸀠 for codons 1339
to 1436; C1: 5󸀠-GGCATTATAAGCCCCAGTGA-3󸀠 and C2:
5󸀠-AAATGGCTCATCGAGGCTCA-3󸀠 for codons 1417 to
1516; and D1: 5󸀠-ACTCCAGATGGATTTTCTTG-3󸀠 and D2:
5󸀠-GGCTGGCTTTTTTGCTTTAC-3󸀠 for codons 1497 to
1596) were used to amplify the mutation cluster region of
the APC gene. For the TP53 gene, the primers used in
the reactions were E5S (5󸀠-TGCCCTGACTTTCAACTCTG-
3󸀠) and E5AS (5󸀠-GCTGCTCACCATCGCTATC-3󸀠) for
exon 5, E6S (5󸀠-CTGATTCCTCACTGATTGCT-3󸀠) and
E6AS (5󸀠-AGTTGCAAACCAGACCTCAGG-3󸀠) for exon
6, E7S (5󸀠-CCTGTGTTATCTCCTAGGTTG-3󸀠) and E7AS
(5󸀠-GCACAGCAGGCCAGTGTGCA-3󸀠) for exon 7, and
E8S (5󸀠-GACCTGATTTCCTTACTGCC-3󸀠) and E8AS (5󸀠-
TCTCCTCCACCGCTTCTTGT-3󸀠) for exon 8. The PCR
products were sequenced using an Applied Biosystems 3100
Avant Genetic Analyzer (Applied Biosystems, Foster City,
CA); the PCRprimerswere also used for sequencing. All APC
and TP53 mutations were confirmed by direct sequencing of
both DNA strands.
2.3. Data Mining. Normalized log2 miR-224 expression
data for the nondrug treated NCI-60 tumor cell line
collection [30] from CellMiner database (http://discover.nci
.nih.gov/cellminer) were analyzed. Among 59 cell lines, 7
CRC cell lines were analyzed with miR-224 expression.
2.4. Cell Lines and Culture. Two CRC cell lines were used
in this study, including APC-mutated HT-29, CaCO
2
and
SW620 cells, and APC-intact HCT-116 cells. Cells were
maintained in RPMI medium supplemented with 10% fetal
bovine serum (FBS) and 1% MycoZap antibiotics (Lonza,
Switzerland). Cells were cultured at 37∘C in a humidified
incubator containing 5% CO
2
.
2.5. miRNA Transfection. The hsa-miR-224-mimicking se-
quenceswere designed and synthesized according to themiR-
Base database (miR-224 mimics; sense: 5󸀠-CAAGUCACU-
AGUGGUUCCGUU-3󸀠 and antisense: 5󸀠-CGGAACCAC-
UAGUGACUUGUU-3󸀠) and a scrambled negative control
(NC mimics; sense: 5󸀠-UUCUCCGAACGUGUCACGUTT-
3󸀠 and antisense: 5󸀠-ACGUGACACGUUCGGAGAATT-
3󸀠) (MDBio, Taipei, Taiwan). The miRNA duplexes were
resuspended in nuclease-free water at a final concentration
of 20𝜇M and stored at −80∘C until used. Cells at 80%
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confluency were transfected with Lipofectamine 2000 (Invit-
rogen, Carlsbad, CA) reagent according to themanufacturer’s
instructions. Six hours after transfection, the medium con-
taining complexes was replaced, and cells were trypsinized
and replated for the following studies.
2.6. Cell Proliferation Assay. miR-224- or NC mimic-
transfectedHCT-116 cells were seeded at 2000 cells per well in
96-well plates and incubated overnight. At the indicated time
point, 10 𝜇L of 10mg/mL of the 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide reagent (Sigma-Aldrich, St.
Louis, MO) was added, and the mixture was allowed to
react for 3 h at 37∘C. Subsequently, the growth medium was
removed, and 200𝜇L of DMSO was added to each well.
The absorbance at an optical density (OD) of 450 nm was
measured with a spectrophotometer.
2.7. siRNATransfection. ThehumanCdc42 siRNA (sc-29256,
Santa Cruz) was applied for silencing Cdc42 expression
according to the manufacturer’s instructions. Six hours
after transfection, the medium containing complexes was
replaced, and cells were trypsinized and replated for the
wound-healing and Boyden chamber migration assays. The
knockdown efficacy (>70%) had been validated by qRT-PCR
and Western blot analysis.
2.8. Wound-Healing Assay. A wound-healing assay was per-
formed by seeding 3× 104miR-224- orNCmimic-transfected
HCT-116 cells into each wound-produced culture insert
(400± 50 𝜇m wide; Ibidi, Martius, Germany) and incubated
overnight. Culture inserts were removed after appropriate cell
attachment and washed twice with phosphate-buffered saline
(PBS), and complete RPMImediumwith 10%FBSwas added.
Cell migration toward the wounded area was observed and
photographed after 24 h. Wound closure (%) was calculated
as the area of migrated cells divided by wounded area at 0 h.
2.9. Boyden Chamber Migration Assay. In the Boyden cham-
ber migration assays, 1 × 105 cells were seeded in 100 𝜇L
serum-free medium atop uncoated membranes with 8𝜇m
pores and translocated toward 500 𝜇L complete media. Cell
migration toward the complete media was stained with 4󸀠,6-
diamidino-2-phenylindole and photographed after 24 h.
2.10. RNA Isolation, Quantitative Reverse-Transcription-
(qRT-) PCR. Total RNA was extracted with the TRIzol
reagent (Invitrogen) according to the manufacturer’s
instructions. Total RNA was quantified using a NanoDrop
spectrophotometer (Thermo Scientific, Asheville, NC). For
the miRNA analysis, 1 𝜇g of RNA was used in a single-round
RT reaction with a miScript Reverse Transcription Kit
according to protocols provided by the supplier for first-
strand complementary (c)DNA synthesis (Qiagen, Valencia,
CA). Expression of mature miRNA was detected with a
miScript SYBR Green PCR Kit (Qiagen) and presented as
−ΔCt (threshold level of fluorescence) values relative to U6-
snRNA: ΔCt = Ct (miR-224) − Ct (U6). In tumor samples,
the definitions of high and low expression of miR-224 were
determined by the mean −ΔCt value (= −5.67) of all patients.
Expression levels higher than the mean were defined as high
expression, and levels lower than the mean were defined as
low expression.
For the messenger (m)RNA analysis, 1 𝜇g of RNA was
used in a single-round RT reaction with a GoScript Reverse
Transcriptase Synthesis Kit according to the protocols pro-
vided by the supplier (Promega, Madison, WI) for first-
strand cDNA synthesis. A quantitative real-time PCR was
performed using a KAPA SYBR FAST qPCR kit (KAPA
Biosystems, Boston, MA) according to the manufacturer’s
protocol, and results were analyzed using a LightCycler
480 Real-Time PCR System in the Core Facility Cen-
ter of the Office of Research and Development at Taipei
Medical University [31]. The following primers were used:
mothers against decapentaplegic homolog 4 (SMAD4): for-
ward 5󸀠-CCATTTCCAATCATCCTGCT-3󸀠 and reverse 5󸀠-
ACCTTTGCCTATGTGCAACC-3󸀠; cell division control
protein 42 homolog (Cdc42): forward 5󸀠-TACTGCAGG-
GCAAGAGGATT-3󸀠 and reverse 5󸀠- CCCAACAAGCAA-
GAAAGGAG-3󸀠; glyceraldehyde 3-phosphate dehydroge-
nase (GAPDH): forward 5󸀠-TCCACTCACGGCAAATTC-
AAC-3󸀠 and reverse 5󸀠-TCCACGACATACTCAGCACC-3󸀠;
and 𝛽-actin: forward 5󸀠-CACCATTGGCAATGAGCGGTT-
C-3󸀠 and reverse 5󸀠-AGGTCTTTGCGGATGTCCACGT-3󸀠
(MDBio). Amplificationswere normalized toGAPDHand𝛽-
actin and calculated using the 2−ΔΔCt method.
2.11. Western Blot Analysis. For total cellular protein extrac-
tion, CRC cells were washed and then lysed in PRO-
PREP protein extraction solution (iNtRON Biotechnology,
Kyungki-Do, Korea). Cleared lysates (30 𝜇g/lane) were sep-
arated by sodium dodecyl sulfate polyacrylamide gel elec-
trophoresis (SDS-PAGE) on 10x gels and electroblotted
onto polyvinylidene difluoride (PVDF) membranes. The
membranes were blocked with 0.5% bovine serum albu-
min (BSA) and then incubated with SMAD4, Cdc42, and
GAPDH antibodies. The bound antibodies were detected
after incubation with a horseradish peroxidase-conjugated
secondary antibody and were visualized by an enhanced
chemiluminescence (ECL) system.
2.12. Measurement of G-Actin/F-Actin Ratio. To determine
the F/G-actin ratio, CRC cells were cultured in 10 cm Petri
dishes at a density of 3 × 105 cells and examined with
an F/G-actin in vivo assay kit (Cytoskeleton, Denver, CO)
based on the manufacturer’s protocol. Briefly, cells were lysed
with cell lysis and F-actin stabilization buffer. After passing
through 25G syringes several times, samples were incubated
at 37∘C for 10min and then centrifuged at 2000 rpm for 5min.
Subsequently, the supernatant was collected and centrifuged
at 105 ×g for 60min at 37∘C. The supernatants (G-actin)
were then separated from the pellets (F-actin) and chilled
on ice. Pellets were resuspended in the same volume as
the supernatants using ice-cold double-distilled (dd)H
2
O
containing 1% cytochalasin D and were incubated on ice for
60min. Equal amounts (15 𝜇L) of samples (supernatant and
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Table 1: Distributions of demographic characteristics of the 18






Age (Mean ± SD) 58.72 ± 16.01 65.42 ± 15.07 0.0958
𝑛 (%) 𝑛 (%)
Gender
Male 8 (44.4%) 35 (44.3%) 0.9914





















pellet) were used for the Western blot analysis with an anti-
actin antibody.
2.13. Statistical Analysis. All datawere analyzed using the Sta-
tistical Package for the Social Sciences version 19.0 software
(SPSS, Chicago, IL). Odds ratios (ORs) and 95% confidence
intervals (CIs) of associations of miR-224 expression levels
with risk, APC and TP53 gene mutations, and clinicopatho-
logical parameters were estimated using multiple logistic
regression models. An unpaired Student’s 𝑡-test was used to
compare between two groups. A probability of <0.05 was
considered statistically significant.
3. Results
3.1. Downregulation of miR-224 Expression in CRC Specimens
and Association with the Mutation Status of the APC Gene.
In order to validate expression levels of miR-224 in CRC
specimens, 97 tissue samples from 79 patients were evaluated
by a real-time RT-PCR assay. Results of the statistical analysis
of demographic characteristics are presented in Table 1.
There were no significant differences in distributions of age
and gender between control subjects and CRC patients.
The expression level of miR-224 was significantly lower
(𝑃 = 0.0047) in CRC compared to normal tissues (as
shown by −ΔCt values of −5.67± 3.28 and −3.21± 2.28, resp.)
(Figure 1(a)). In comparison with 18 paired specimens, the
expression level ofmiR-224was also lower (𝑃 = 0.0447) in the
tumor samples (−ΔCt values of tumor and adjacent samples;
−4.75± 2.83 and −3.21± 2.28, resp.) (Figure 1(b)).
The total primary CRC samples were divided into two
groups using themean value ofmiR-224 (mean value:−ΔCt =
−5.67; miR-224-high and -low, resp.), and distributions of the
age, gender, clinical stages, tumor T status, lymph node, and
distant metastasis and APC and TP53 gene mutation status
in CRC samples are given in Table 2. A significantly larger
number of CRCpatients carrying themutatedAPCgenewere
found in the miR-224-high group compared to the miR-224-
low group (OR = 3.643; 95% CI: 1.297∼10.228, 𝑃 = 0.015).
However, no associations were found for the miR-224-high
and -low groups with age, gender, clinical stages, tumor T
status, lymph node, and distant metastasis or the TP53 gene
mutation status.
3.2. A Higher miR-224 Expression Level Suppressed the Migra-
tory Ability of CRC Cell Line. The expression profiles of miR-
224 were analyzed in nondrug treated NCI-60 tumor cell line
CellMiner Database. All 7 CRC cell lines in NCI-60 panel
were selected and analyzed; APC-mutated CRC cell lines,
except for KM12, tend to express more miR-224 than APC
gene-intact HCT-116 cell line (Figure 2(a)). In addition, four
humanmalignant CRC cell lines with different statuses of the
APC gene were selected to validate the miR-224 expression
levels. Results also showed that the APC gene-mutated HT-
29, CaCO
2
, and SW620 cell lines presented higher miR-
224 expression level than the APC gene-intact HCT-116 cell
line (Figure 2(b)). To gain further insights into the role of
miR-224 in CRC malignancy, we transfected either NC or
miR-224 mimics into HCT-116 cells to analyze the biological
effects on cell growth and themigratory ability. HCT-116 cells
transfectedwithmiR-224mimics expressed an approximately
600-fold higher miR-224 level than NC mimics at 48 h
after transfection (Figure 2(c)). The cell growth rate showed
no significant differences in HCT-116 cells transfected with
either the NC or miR-224 mimic (Figure 2(d)). Compared
to NC mimic-transfected HCT-116 cells, miR-224 mimic-
transfected cells exhibited a significant reduction in the
migration ability in the in vitro wound-closure assay and
Boyden chamber migration assay (Figures 2(e) and 2(f)). It
should be noted thatHT-29 cells showed a very lowmigration
ability in the wound healing assay (<5% wound healing
closure at 24 h, data not shown), which may be partly caused
by the APC mutation mediated miR-224 overexpression.
These results suggest that the increased miR-224 expression
negatively regulates the migratory ability of CRC cells.
3.3. Ectopic Expression of miR-224 Diminished Cdc42 and
SMAD4 Expressions and Inhibited the Formation of Actin
Filaments. Because of the miR-224 participated in regu-































Figure 1: The expression level of miR-224 is repressed in colorectal cancer (CRC) specimens. (a) The level of miR-224 expression in CRC
tissues (𝑛 = 79) was lower than that in control tissues (𝑛 = 18). (b) The level of miR-224 expression in 18 paired specimens. Values shown
(−ΔCt) are related to those of U6-snRNA (∗∗𝑃 < 0.01).
may be involved in metastatic progression. SMAD4 and
Cdc42 are both putative miR-224 targets, which were previ-
ously reported to be related to CRC metastasis. In search-
ing through the Sloan-Kettering Cancer Center Human
MicroRNA Targets Database [32], miR-224 was predicted
with good mirSVR scores when targeting three different
sequence sites on SMAD4 and one on Cdc42 (Figure 3(a)).
Therefore, we further analyzed whether ectopic expression
of miR-224 affected endogenous expressions of SMAD4 and
Cdc42. Forty-eight hours after transfection, both the mRNA
and protein levels of SMAD4 and Cdc42 were noted to be
suppressed in miR-224-transfected HCT-116 cells (Figures
3(b) and 3(c)). The phenomenon of a cancer cell migrating
throughmodifying the shape and stiffness of the surrounding
tissue structures is controlled by dynamic changes in the
actin cytoskeleton and leads to interactions with extracellular
matrix (ECM) substrates. Cdc42 is a small GTP-binding
protein which can regulate the formation of actin filament-
based structures. As shown in Figure 3(d), miR-224 mimic-
transfected HCT-116 cells showed decreased formation of
filamentous actin compared to NC mimics (Figure 3(d)). In
addition, silencing Cdc42 had decreased the migration of
HCT-116 as compared to transfection reagent (TR) alone.
Cotransfected with 224M in Cdc42i, treated cells showed
no significant differences as compared to those cotransfected
either with NCM or Cdc42i alone (Figures 3(e) and 3(f)).
These findings suggest that miR-224 may regulate CRC
cell migration, at least in part, through inhibiting Cdc42
expression and suppressing filamentous actin-mediated cell
migration.
4. Discussion
In the current study, according to a quantitative real-time
PCR analysis, the expression level of miR-224 was lower in
CRC specimens compared to normal tissues. The miR-224
expression level was not associated with age, gender, clinical
parameters, or the TP53 status, while the expression level
was associated with the mutation status of the APC gene.
The HCT-116 cell migration ability was suppressed by ectopic
expression ofmiR-224 through diminishingCdc42-mediated
filamentous actin formation. These findings suggest that
downregulation of miR-224 increased cancer cell migration
in CRC and thus may, at least in part, participate in CRC
metastasis.
The expression level of miR-224 increased between nor-
mal tissues and the early stage of CRC but did not show
significant differential expression between the early and late
stages in a global CRC specimen miRNA analysis [12].
Recently, Yuan et al. found that levels of miR-224 were
reduced inmetastatic, compared to nonmetastatic, CRC cells.
Expression levels in human tumor samples were inversely
correlated with the tumor stage, metastasis to lymph nodes,
and patient survival times, but no differences were observed
between normal and tumor samples [33]. In this study, miR-
224 exhibited lower expression in tumor samples than normal
samples (Figure 1). In addition, its expression level was not
related to clinical parameters (i.e., age, gender, TMN stage,
or differentiation) or the status of the TP53 mutation, while
it was related to the status of the APC mutation (Table 2).
These findings suggest that differences inmiR-224 expression
levels in the pathogenesis of CRC may be related to racial
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Odds ratio (95% CI) 𝑃 value
Age
≤68 (median age) 19 (47.5%) 21 (53.8%) 1.29 (0.533∼3.121) 0.573
>68 (median age) 21 (52.5%) 18 (46.2%)
Gender
Female 21 (52.5%) 14 (35.9%) 0.507 (0.206∼1.248) 0.140
Male 19 (47.5%) 25 (64.1%)
Clinical stage
Stage I/II 23 (57.5%) 20 (51.3%) 1.285 (0.529∼3.121) 0.579
Stage III/IV 17 (42.5%) 19 (48.7%)
Tumor T status
≤2 5 (12.5%) 6 (15.4%) 0.786 (0.219∼2.822) 0.712
>2 35 (87.5%) 33 (84.6%)
Lymph node metastasis
No 24 (60%) 20 (51.3%) 1.425 (0.584∼3.475) 0.436
Yes 16 (40%) 19 (48.7%)
Distant metastasis
No 36 (90%) 37 (94.9%) 0.487 (0.084∼2.823) 0.422
Yes 4 (10%) 2 (5.1%)
APC
Normal 33 (82.5%) 22 (56.4%) 3.643 (1.297∼10.228) 0.015
Mutated 7 (17.5%) 17 (43.6%)
TP53
Normal 11 (27.5%) 11 (28.2%) 0.966 (0.361∼2.583) 0.945
Mutated 29 (72.5%) 28 (71.8%)
aSamples expressed miR-224 at lower than the average −ΔCt value.
bSamples expressed miR-224 at higher than the average −ΔCt value.
CI: confidence interval.
and environmental diversity; however, this inference requires
further investigation.
Regulation ofmiR-224 expression was reported in several
different cell types. In transforming growth factor (TGF)-𝛽1-
stimulated mouse ovarian granulosa cells, miR-224 expres-
sion was regulated by the TGF-𝛽/SMADs pathway [34].
Overexpression of Src in mouse embryonic Cx43Ko brain
cells also increased miR-224 expression [35]. In addition,
the E2-conjugating enzyme, Ubc9, that transfers an acti-
vated small ubiquitin-related modifier to protein substrates
can suppress miR-224 expression in breast cancer cells. In
the current study, a significantly higher number of CRC
patients carrying the mutated APC gene were found in the
miR-224-high group compared to the miR-224-low group.
In addition, miR-224 was also more highly expressed in
three APC-mutated cell lines than APC-intact HCT-116 cells
(Figure 2(a)). APC is a negative regulator of the Wnt/ß-
catenin/TCF pathway, which is involved in both carcinogene-
sis [36] and normal intestinal homeostasis [37].MutatedAPC
can cause familial adenomatous polyposis and is mutated in
the vast majority of all sporadic colorectal cancers [38]. In
the absence ofWnt signaling,𝛽-catenin undergoes ubiquitin-
mediated degradation by amultiprotein destruction complex,
composed of the tumor suppressor APC, Axin, protein
phosphatase 2A, glycogen synthase kinase 3, and casein
kinase 1𝛼 [39]. Defect of APC leadsWnt signaling constitutive
transcriptional activation through the nuclei accumulation
of a 𝛽-catenin/TCF transcription factor complex [40]. The
genetic location of miRNA-224 is within a 200 kb region of
Xq28 in close proximity to miR-452 within the GABRE gene
and is flanked by the MAGEA4 and MAGEA5 cancer anti-
gens [34]. In addition, the GABRE gene had been reported
exclusively overexpressed with Wnt pathway activation [41].
These evidences suggested that the increase of miR-224 in
APC-mutated CRC cells may be regulated by the constitutive
activation of Wnt/ß-catenin/TCF pathway. Therefore, the
APCmutation activates theWnt signal pathway andmediates
an increase in miR-224, which may serve as a negative
regulator of cell motility and metastasis.
The multifaceted involvement, including cell prolifer-
ation, migration, invasion, and apoptosis, of miR-224 in













































































































































































Figure 2: Increased miR-224 expression suppressed the colorectal cancer (CRC) cell migration ability but not cell proliferation. (a)
Normalized log
2
miR-224 expression data in CRC cell lines from the nondrug treated NCI-60 tumor cell line collection. (b) Real-time RT-
PCR analysis of miR-224 expression levels in HT-29 and HCT-116 cells. (c) Real-time RT-PCR analysis of miR-224 expression levels in NCM-
and 224M-transfected HCT-116 cells. (d) Proliferation potential of NCM- and 224M-transfected HCT-116 cells. (e, f) Migratory ability of
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Figure 3: Increased miR-224 expression diminished Cdc42 and SMAD4 expressions and inhibited the formation of actin filaments. (a)
Prediction of miR-224 targeting mRNA sequences on SMAD4 and Cdc42 in the Sloan-Kettering Cancer Center Human MicroRNA Targets
Database. (b, c) mRNA and protein levels of SMAD4 and Cdc42 in NCM- and 224M-transfected HCT-116 cells (∗𝑃 < 0.05; ∗∗𝑃 < 0.01). (d)
Representative Western blot of G- and F-actin from NCM- and 224M-transfected HCT-116 cells. Data are from one of three experiments. (e,
f) Migratory ability of Cdc42 silenced HCT-116 cells transfected with NCM and 224M (∗𝑃 < 0.05, compared to TR alone).
was the most significantly upregulated miRNA in HCC
patients, and it was revealed that miR-224 increased both
apoptotic cell death and proliferation [42]. Here, ectopic
miR-224 expression decreased HCT-116 cell migration but
not cell proliferation (Figures 2(c)–2(f)); this indicates that
expression of miR-224 in CRC manifests the potential for
the cell migration ability. However, there was no significant
decrease in the miR-224 level observed between metastatic
and nonmetastatic patients in this study. In addition to the
limited number of metastatic patients, only primary tumor
samples were collected to evaluate miR-224 in this study,
thus limiting our current findings on the clinical association
between miR-224 expression levels and metastasis [29].
Several putative targets of miR-224 were validated to be
involved in regulating cell proliferation, migration, and inva-
sion, such as apoptosis inhibitor-5 [42], RKIP [17], SMAD4
[34], Cdc42, and CXCR4 [43]. In this study, miR-224 showed
participation in CRC cell migration; its putative targets
related to the cell-migration ability, SMAD4 and Cdc42,
were selected for further investigation. Ectopic expression of
miR-224 inhibited both the mRNA and protein expressions
of SMAD4 and Cdc42 (Figures 3(b) and 3(c)), which may
result in suppression of the in vitro HCT-116 cell migration
ability (Figures 2(e) and 2(f)). It was reported that loss of
SMAD4 in CRC cells plays an important role in increasing
the tumorigenic andmetastatic potential [44]. A recent study
indicated that miR-224 can inhibit SMAD4 expression to
increase SW480 cell migration and invasion ability [45].
However, loss in the TGF-𝛽 receptor or SMAD4 commonly
occurs in sporadic CRC patients and cell lines, such as
SW480, HT-29, SW620 (absent SMAD4 protein and allelic
loss at SMAD4), CaCO
2
(SMAD4 point mutations and rapid
SMAD4 protein degradation), and HCT-116 (mutation in
TGFBIIR) [46]. Therefore, miR-224 diminishing the HCT-
116 cell-migration ability might not be mediated through
direct targeting of the TGF-𝛽/SMAD4 pathway. In contrast,
Cdc42 is involved in regulating the rearrangement of the
actin cytoskeleton, and it was found to be overexpressed
with a high incidence in CRC samples [47]. Overexpression
of miR-224 reduced cytoskeletal composition changes from
global- to filamentous-actin (Figure 3(d)), which suppressed
the cell motility and the formation of lamellipodia, thereby
diminishing CRCmigration. In addition to directly targeting
Cdc42, decreased levels of miR-224 also increased methyl-
CpG-binding domain protein 2 gene expression, thereby sup-
pressing maspin and promoting CRC growth and metastasis
[33].
In summary, we investigated expression levels of miR-224
in CRC clinical specimens and its biological functions. The
expression levels of miR-224 were lower in CRC tissues and
its expression level was associated with the mutation status of
the APC gene. A reduction in mR-224 expression may cause
epigenetic regulation of CRC metastasis through targeting
Cdc42 and may be considered as a potential predictive
biomarker for CRC progression.
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